scholarly journals Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients

2017 ◽  
Vol 23 (4) ◽  
pp. 461-464 ◽  
Author(s):  
Kimberly DeLeonardis ◽  
Kristin Sedgwick ◽  
Olga Voznesensky ◽  
Ellen Matloff ◽  
Erin Hofstatter ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Germline Mutations ◽  
Breast And Ovarian Cancer

scholarly journals High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area

2005 ◽  
Vol 7 (5) ◽  
Author(s):  
Petr Pohlreich ◽  
Michal Zikan ◽  
Jana Stribrna ◽  
Zdenek Kleibl ◽  
Marketa Janatova ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Brca1 Gene ◽  
Germline Mutations ◽  
Breast And Ovarian Cancer

High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients

2018 ◽  
Vol 168 (3) ◽  
pp. 695-702 ◽  
Author(s):  
Al-Joharah Alhuqail ◽  
Areej Alzahrani ◽  
Hannah Almubarak ◽  
Sarah Al-Qadheeb ◽  
Lamyaa Alghofaili ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Germline Mutations ◽  
Breast And Ovarian Cancer ◽  
Brca1 And Brca2 ◽  
High Prevalence

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients

2011 ◽  
Vol 33 (1) ◽  
pp. 95-99 ◽  
Author(s):  
Ella R. Thompson ◽  
Samantha E. Boyle ◽  
Julie Johnson ◽  
Georgina L. Ryland ◽  
Sarah Sawyer ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Germline Mutations ◽  
Breast And Ovarian Cancer ◽  
High Risk Breast

scholarly journals RAD51C germline mutations in breast and ovarian cancer patients

2010 ◽  
Vol 12 (4) ◽  
Author(s):  
Mohammad R Akbari ◽  
Patricia Tonin ◽  
William D Foulkes ◽  
Parviz Ghadirian ◽  
Marc Tischkowitz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Germline Mutations ◽  
Breast And Ovarian Cancer

scholarly journals Therapy Related Myeloid and Lymphoid Neoplasms in BRCA Mutated Breast and Ovarian Cancer Patients

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5115-5115
Author(s):  
Mohammad M Mirza ◽  
Brennan Mccular ◽  
Michael G Martin
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Dna Damage ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Stage Iv ◽  
Germline Mutations ◽  
Breast Cancer Patients ◽  
Breast And Ovarian Cancer ◽  
Brca1 And Brca2

Abstract Background The treatment of breast and ovarian cancer is associated with a small risk of therapy related myeloid/lymphoid neoplasms (t-MLN).The outcomes of t-MLN are dismal. It is unknown whether germline mutations in DNA damage repair mechanisms increase the risk of t-MLN when patients are exposed to chemotherapy and/or radiation therapy. Germline mutations in BRCA1 and BRCA2 reduce the ability of both neoplastic and normal cells to repair of DNA damage from environmental stressors or chemotherapy. Mutations in TP53, another DNA damage repair gene, have been demonstrated to be selected for by chemotherapy and be associated with t-MLN. Therefore, we hypothesize that breast and ovarian cancer patients with germline mutations in BRCA1 and BRCA2 are at higher risk for developing t-MLN when compared to the patients receiving chemotherapy and/or radiation therapy for breast or ovarian cancer without BRCA 1 and BRCA 2 germline mutations. Methods Under an IRB approved protocol patients with BRCA1/2 mutated breast or ovarian cancer treated at West Cancer Center (WCC) between January 2006 to December 2015 were identified using a genetic database search. Demographics were obtained including age of diagnosis, specific BRCA germline mutation, chemotherapy or targeted therapy used, receipt of radiation therapy, and stage of disease. t-MLN was defined as any myeloid malignancy or acute lymphoblastic leukemia (MDS, AML or ALL) diagnosed with a latency of at least 12 months after receipt of the first dose of chemotherapy or radiation therapy. Patients that were identified that did not receive therapy were also evaluated and followed for incidence of second primary malignancy. The incidence of t-MLN for patients diagnosed with BRCA mutated breast or ovarian cancer was compared to the reported expected incidence of t-MLN from the SEER database (MP-SIR session, SEER 9 Nov 2015, 1973-2013) for the corresponding time period. Patients will continue to be followed through the electronic medical record (EMR) for up to 10 years from the receipt of therapy. Analyses were conducted used Microsoft Excel 14.5.7, Seer*STAT and GraphPad prism version 6. The dataset will be updated annually for t-MLN incidence. Results Seventy-Eight patients with BRCA mutated breast or ovarian cancers were identified with median follow up of 3.3 (range 0.6 - 13.9) years from date of diagnosis. Seventy-seven patients were female and one was male. Median age was 47 (25-74). 70% (n = 55) patients were Caucasians, 26% (n = 20) were African-Americans and 4% were others (n = 3). 72% (n = 56) patients had breast cancer, 22% (n = 17) had ovarian cancer and 6% (n = 5) had both. BRCA mutations were distributed with 49% (n = 38) BRCA1 and 51% (n = 40) BRCA2. 46% (n = 28) of breast cancer had BRCA1 mutations and 54% (n = 33) had BRCA2 mutations. 55% (n = 12) of ovarian cancer had BRCA1 mutations and 45% (n = 10) had BRCA2 mutations. Stage distribution of breast cancer patients was, stage I 30% (n = 18), stage II 38% (n = 23), stage III 19% (n = 11), stage IV 5% (n = 3) and stage was unknown in 8% (n = 5). Stage distribution of ovarian cancer patients was, stage I 5% (n = 1), stage II 10% (n = 2), stage III 50% (n = 11), stage IV 35% (n = 8). 93% (n = 57) of breast cancer patients received chemotherapy including 66% (n = 40) that received anthracycline-containing regimens. 7% (n = 4) of breast cancer patients received no chemotherapy. 100% (n = 22) of ovarian cancer patients received chemotherapy and 100% of them received platinum containing regimens. 44% (n = 27) of patients received radiation therapy (all breast cancer). One patient (1.3%) with a BRCA1 mutation 1996ins4 and stage IV ovarian cancer developed t-AML after receiving five lines of therapy including olaparib 66 months after receipt of first chemotherapy and succumbed to her disease one month later. During the same time period (2006+) 14 women (0.6%) in the SEER database developed t-MLN (13 AML and 1 ALL) out of 2,533 women with a diagnosis of breast cancer. There is no observed difference in the incidence of t-MLN in our BRCA1/2 germline mutated patients and the SEER population (Fisher's exact 0.366, Odds ration 2.34 [0.30-18]). Conclusion: With 3.3 years of median follow-up our dataset is still immature but to date there is no observed increased risk of t-MLN in patients with BRCA1/2 germline mutations. We will continue to follow these women prospectively for further events and update the dataset annually. Disclosures No relevant conflicts of interest to declare.

Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.

1998 ◽  
Vol 16 (2) ◽  
pp. 397-404 ◽  
Author(s):  
O T Jóhannsson ◽  
J Ranstam ◽  
A Borg ◽  
H Olsson
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Matched Control ◽  
Brca1 Mutation ◽  
Population Based ◽  
Control Group ◽  
Breast And Ovarian Cancer ◽  
Population Based Study ◽  
Matched Control Group ◽  
Group Survival

PURPOSE Recent studies indicate that BRCA1 breast and ovarian tumors may have an advantageous survival. In this population-based study, the survival of carriers of a mutated BRCA1 gene was investigated. PATIENTS AND METHODS The survival of 71 BRCA1-associated cancer patients (33 breast cancer, seven breast and ovarian cancer, and 31 ovarian cancer patients from 21 families with BRCA1 germline mutations) diagnosed after 1958 was compared with that of a population-based comparison group that consisted of all other invasive breast (n = 28,281) and ovarian (n = 7,011) cancers diagnosed during 1958 to 1995, as well as an age- and stage-matched control group. RESULTS No apparent survival advantage was found for BRCA1-associated breast cancers upon direct comparison. After adjustment for age and calendar year of diagnosis, survival was equal to or worse than that of the comparison group (hazards ratio [HR], 1.5; 95% confidence interval [CI], 0.9 to 2.4). In comparison with an age- and stage-matched control group, survival again appeared equal or worse (HR, 1.5; 95% CI, 0.6 to 3.7). For BRCA1-associated ovarian cancers, an initial survival advantage was noted that disappeared with time. Due to this time dependency, multivariate analyses cannot adequately be analyzed. Compared with the age- and stage-matched control group, survival again appeared equal or worse (HR, 1.2; 95% CI, 0.5 to 2.8). CONCLUSION The results suggest that survival for carriers of a BRCA1 mutation may be similar, or worse than, that for breast and ovarian cancer in general. This finding is in accordance with the adverse histopathologic features observed in BRCA1 tumors and underlines the need for surveillance in families that carry a BRCA1 mutation.

scholarly journals Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer

2015 ◽  
Vol 3 (5) ◽  
pp. 459-466 ◽  
Author(s):  
Yosuke Hirotsu ◽  
Hiroshi Nakagomi ◽  
Ikuko Sakamoto ◽  
Kenji Amemiya ◽  
Toshio Oyama ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Dna Repair ◽  
Germline Mutations ◽  
Dna Repair Genes ◽  
Panel Analysis ◽  
Breast And Ovarian Cancer ◽  
Repair Genes ◽  
Multigene Panel
Sign in / Sign up

Export Citation Format

Share Document